Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is updating its global biopharma coverage forecasts ahead of Q4 earnings following check-ins with investor relations teams and recent public commentary, the analyst tells investors in a preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Calquence combination approved in U.S.
- Drugmakers to push Trump to pause price negotiations, Bloomberg reports
- Ionis unveils pipeline plan for 2025, expects 4 independent product launches
- Compugen initiated with an Outperform at Oppenheimer
- AstraZeneca, Daiichi Sankyo datopotamab deruxtecan BLA granted priority review